Pàgina d'iniciRDY • NYSE
add
Dr Reddy's Laboratories Ltd
Tancament anterior
14,14 $
Interval anual
12,90 $ - 16,89 $
Capitalit. borsària
11,78 kM USD
Volum mitjà
915,79 k
A les notícies
Finances
Balanç de resultats
Ingressos
Ingressos nets
(INR) | set. del 2024info | Variació interanual |
---|---|---|
Ingressos | 80,16 kM | 16,51 % |
Despesa d'explotació | 29,72 kM | 24,54 % |
Ingressos nets | 12,55 kM | -15,18 % |
Marge de benefici net | 15,66 | -27,20 % |
Benefici per acció | 15,83 | -11,13 % |
Ebitda | 22,02 kM | 8,53 % |
Taxa impositiva efectiva | 30,01 % | — |
Balanç
Actiu total
Passiu total
(INR) | set. del 2024info | Variació interanual |
---|---|---|
Efectiu i invers. a curt terme | 63,07 kM | -7,15 % |
Actiu total | 465,96 kM | 34,27 % |
Passiu total | 156,67 kM | 66,79 % |
Capital total | 309,28 kM | — |
Accions en circulació | 833,05 M | — |
Ràtio cotització-valor | 0,04 | — |
Rendiment | 10,24 % | — |
Rendibilitat d'inversió | 13,21 % | — |
Flux de caixa
Variació neta de l'efectiu
(INR) | set. del 2024info | Variació interanual |
---|---|---|
Ingressos nets | 12,55 kM | -15,18 % |
Efectiu d'operacions | 9316,00 M | -48,03 % |
Efectiu d'inversió | -19,07 kM | -322,21 % |
Efectiu de finançament | 16,15 kM | 329,53 % |
Variació neta de l'efectiu | 6372,00 M | 1,03 % |
Flux de caixa lliure | 3915,00 M | -72,47 % |
Informació
Dr. Reddy's Laboratories is an Indian multinational pharmaceutical company based in Hyderabad. The company was founded by Kallam Anji Reddy, who previously worked in the mentor institute Indian Drugs and Pharmaceuticals Limited. Dr. Reddy manufactures and markets a wide range of pharmaceuticals in India and overseas. The company produces over 190 medications, 60 active pharmaceutical ingredients for drug manufacture, diagnostic kits, critical care, and biotechnology.
Dr. Reddy's began as a supplier to Indian drug manufacturers, but it soon started exporting to other less-regulated markets that had the advantage of not having to spend time and money on a manufacturing plant that would gain approval from a drug licensing body such as the U.S. Food and Drug Administration. By the early 1990s, the expanded scale and profitability from these unregulated markets enabled the company to begin focusing on getting approval from drug regulators for their formulations and bulk drug manufacturing plants – in more-developed economies. This allowed their movement into regulated markets such as the US and Europe.
By 2007, Dr. Wikipedia
Conseller delegat, CO
Data de fundació
1984
Seu principal
Lloc web
Empleats
27.048